No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
688520 Sinocelltech Inc.
- 36.41
- +1.81+5.23%
Market Closed Jan 20 15:00 CST
16.21BMarket Cap-617.12P/E (TTM)
37.19High35.20Low31.86KlotVolume35.29Open34.60Pre Close116.17MTurnover0.72%Turnover RatioLossP/E (Static)445.34MShares52.6052wk High-37.85P/B16.21BFloat Cap31.0752wk Low41.52Limit Up445.34MShs Float103.99Historical High27.68Limit Down5.75%Amplitude31.07Historical Low--Dividend TTM36.46Avg Price13.39KlotAsk--Div YieldTTM100Lot Size16.71KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Shenzhou Cell 2024 Annual Results Pre-Profit Announcement
Express News | Shenzhou Cell: It is expected that the net income in 2024 will be between 90 million yuan and 0.13 billion yuan.
Shenzhou Cell (688520.SH): The company has no layout in the development of new stem cell products and regenerative medicine.
Gelonghui, November 15丨Shenzhou Cell (688520.SH) investor relations activity record shows that the company has no layout in the development of new stem cell products and regenerative medicine.
Shenzhou Cell (688520.SH): The SCT-I10A monoclonal antibody has two indications for liver cancer and head and neck cancer in the market approval stage.
Gelonghui November 15th 丨 Investor Relations Activity Record of Shenzhou Cell (688520.SH) shows that SCT-I10A monoclonal antibody has two indications for liver cancer and head and neck cancer in the market approval stage, with no other indications currently planned for market approval.
Shenzhou Cell (688520.SH): plans to conduct perpetual debt financing of up to 0.8 billion yuan with its controlling shareholder, Lhasa Ailik.
Gelonghui, November 15 - The investor relations activity record for Shenzhou Cell (688520.SH) shows that the company plans to conduct perpetual bond financing of no more than 0.8 billion yuan from its controlling shareholder, Lhasa Ailike. This perpetual bond financing proposal has been approved at the 12th meeting of the second board of directors and the second extraordinary general meeting of shareholders in 2024. The funds from the perpetual bond financing will be in place before the end of 2024, ensuring that the company’s net assets can turn positive.
Shenzhen SinoCell (688520.SH): The 14-valent HPV vaccine trial participants have completed the third dose and are now in the follow-up stage.
Gelonghui November 15th | Shenzhou Cell (688520.SH) Investor Relations Activity Record shows that the 14-valent HPV vaccine subjects have completed the third dose vaccination and are currently in the follow-up stage. The related research and development progress and data analysis are voluntary disclosure information by the company. The company will disclose information in accordance with laws and regulations based on business progress.
